Clover Health Investments, Corp. (CLOV) has a negative trailing P/E of -11.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 47.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -8.64%, forward earnings yield 2.10%. PEG 0.80 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -2.1 | 0.00 | -7.82 | 1.52 | - |
| 2019 | -11.3 | 0.14 | -233,979.71 | 8.92 | - |
| 2020 | -49.7 | 0.67 | -10.99 | 10.08 | - |
| 2021 | -3.0 | -0.01 | 3.27 | 1.19 | - |
| 2022 | -1.3 | 0.03 | 1.24 | 0.40 | - |
| 2023 | -2.2 | 0.06 | 1.60 | 0.36 | - |
| 2024 | -35.9 | 0.45 | 4.52 | 1.13 | - |
| 2025 | -14.2 | -0.15 | 3.94 | 0.63 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-4.81 | $281.02M | $-201.93M | -71.9% |
| 2019 | $-0.90 | $462.27M | $-363.74M | -78.7% |
| 2020 | $-0.23 | $672.89M | $-136.39M | -20.3% |
| 2021 | $-1.25 | $1.47B | $-587.76M | -39.9% |
| 2022 | $-0.71 | $1.1B | $-339.57M | -31% |
| 2023 | $-0.45 | $1.26B | $-213.36M | -16.9% |
| 2024 | $-0.08 | $1.37B | $-43.01M | -3.1% |
| 2025 | $-0.17 | $1.92B | $-85.55M | -4.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.04 | $0.04 – $0.04 | $2.88B | $2.85B – $2.91B | 1 |
| 2027 | $0.05 | $0.05 – $0.05 | $3.32B | $3.29B – $3.35B | 1 |
| 2028 | $0.12 | $0.06 – $0.18 | $3.7B | $3.7B – $3.7B | 2 |
| 2029 | $0.21 | $0.21 – $0.21 | $4.31B | $4.27B – $4.35B | 1 |
| 2030 | $0.28 | $0.28 – $0.28 | $4.8B | $4.76B – $4.85B | 1 |
